Cooley M&A

JANUARY 22, 2020

billion – almost double the value of deals announced in that same sector in 2018, despite the number of deals decreasing from 705 in 2018 to 519 in 2019. billion; Audentes Therapeutics’ sale to Astellas for $3 billion; Ra Pharmaceuticals’ pending sale to UCB for $2.5 billion; and Synthorx’s sale to Sanofi $2.5

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

JULY 9, 2021

In the Delaware appraisal decisions that have followed, the court has consistently found deal price (minus synergies) to be the most reliable indicator of fair value, so long as there was a sufficiently robust sales process that bore “objective indicia” of reliability. Panera Bread was a publicly traded company that JAB Holdings B.V.

Mergers and Acquisitions 52

Mergers and Acquisitions Sale Shares Entertainment 52

Software Equity Group

FEBRUARY 28, 2023

Stock prices and valuations of many leading public SaaS companies have fallen drastically from the beginning of 2022—but while that will affect the private market, it does not necessarily spell doom and gloom. This post will examine the current state of public SaaS company valuations and what it means for private companies.

Valuation 52

Valuation M&A Stock Profitability 52

Cooley M&A

SEPTEMBER 16, 2022

In addition, currently public dual-class companies with transfer provisions that do not contain clear carve outs for the delivery of voting agreements in the M&A context should discuss with their advisers the possibility of adopting “clear day” amendments to their charters to include these carve outs. Vote-down termination fee (i.e.,

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Cooley M&A

OCTOBER 29, 2020

As reflected in Chart 1 , 102 SPAC IPOs have been announced this year as of September 18, 2020—almost double the number of SPAC IPOs in all of last year (and more than double the number of SPAC IPOs in 2018). Revisiting Governance Documentation.

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Focus Investment Banking

FEBRUARY 11, 2025

McKesson, a public company with approximately $76 billion in market value, will purchase an 80% interest in PRISM for approximately $850M. PRISM was founded in 2018 with Quad-C Managements acquisition of NJ Retina, a large Retina practice in New Jersey.

Private Equity 52

Private Equity Healthcare Equities Medical 52